IP Library Granted Patent US 7,790,102
Granted Patent B2
US 7,790,102 · App. 10/538,777 · Granted Sep 7, 2010

Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis

Assignee: Gambro Lundia AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,102
App. No.
10/538,777
Granted
Sep 7, 2010
Kind
B2
Abstract

Method for preparing a medical solution, comprising the steps of a) providing a solution comprising one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container at a pH from 2.5 to 5.0, and b) terminal sterilization of said at least one compartment and the contents therein, is disclosed, as well as a solution used for preparing the medical solution, a container containing said solution, and use of said solution for the manufacture of a medicament for peritoneal dialysis.

Claims (21)

1. A method for preparing a medical solution, comprising the steps of:

a) providing a solution comprising one or more acetylated or deacetylated amino sugars in at least one compartment of a container, said solution having a pH of 2.5-3.5, and

b) terminally sterilizing of said at least one compartment and the solution therein to form a terminally sterilized solution, wherein the terminally sterilized solution contains low levels of cytotoxic degradation products; and wherein the one or more acetylated or deacetylated amino sugars is N-acetylglucosamine.

2. The method according to claim 1 , wherein said N-acetylglucosamine is present in a concentration of 15-40% by weight with respect to the weight of the solution in said at least one compartment.

3. The method according to claim 2 , wherein said N-acetylglucosamine is present in a concentration of 20-40% by weight with respect to the weight of the solution in said at least one compartment.

4. The method according to claim 3 , wherein said N-acetylglucosamine is present in a concentration of at least 30% by weight with respect to the weight of the solution in said at least one compartment.

5. The method according to claim 1 , wherein the terminal sterilisation is heat sterilisation at a temperature of at least 100° C.

6. The method according to claim 5 , wherein the terminal sterilisation is heat sterilisation at a temperature of 121° C.

7. The method according to claim 1 , wherein each compartment of the container is delimited from other compartments during the terminal sterilisation, and wherein the terminally sterilised solution containing N-acetylglucosamine is mixed with a terminally sterilised pH adjusting and diluting solution in at least one other terminally sterilised compartment of the container, thereby finally preparing the medical solution.

8. The method according to claim 7 , wherein the pH in the finally prepared medical solution is 6.0-8.0.

9. The method according to claim 8 , wherein the pH in the finally prepared medical solution is 7.4.

10. The method according to claim 7 , wherein the concentration of N-acetylglucosamine in the finally prepared solution is 0.2-15.0% by weight.

11. The method according to claim 10 , wherein the concentration of N-acetylglucosamine in the finally prepared solution is 0.5-6.0% by weight.

12. The method according to claim 1 , wherein physiologically compatible constituents in the form of carbohydrates, proteins, peptides, and antioxidants are present in one or more of said compartments.

13. The method according to claim 12 , wherein the carbohydrate is glucose.

14. The method according to claim 1 , wherein the medical solution prepared is a peritoneal dialysis solution.

15. The method according to claim 1 , wherein the pH is 3.0.

16. The method according to claim 1 , wherein the terminal sterilisation is radiation sterilisation.

17. A method for preparing a medical solution, comprising the steps of:

a) providing a solution comprising one or more acetylated or deacetylated amino sugars in at least one compartment of a container, said solution having a pH of 2.5-3.5, and

b) terminally sterilizing of said at least one compartment and the solution therein to form a terminally sterilized solution, wherein the terminally sterilized solution results in lower levels of inhibition of cell growth compared to a solution terminally sterilized at a pH outside the range of 2.5-3.5, and wherein the one or more acetylated or deacetylated amino sugars is N-acetylglucosamine.

Assignments (7)
MERGER AND CHANGE OF NAME Recorded Feb 28, 2025
From: SYNGENTA PARTICIPATIONS AG; SYNGENTA PARTICIPATIONS AG
To: SYNGENTA CROP PROTECTION AG
Reel/Frame 070363/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2018
From: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
To: GAMBRO LUNDIA AB
Reel/Frame 047419/0647 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Dec 29, 2011
From: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT
To: GAMBRO LUNDIA AB
Reel/Frame 027456/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2011
From: GAMBRO LUNDIA AB
To: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
Reel/Frame 026850/0625 →
RELEASE OF SECURITY INTEREST Recorded Jan 7, 2011
From: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT
To: GAMBRO LUNDIA AB
Reel/Frame 025600/0276 →
IP SECURITY AGREEMENT SUPPLEMENT Recorded May 21, 2009
From: GAMBRO LUNDIA AB
To: CITICORP TRUSTEE COMPANY LIMITED
Reel/Frame 022714/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2005
From: CARLSSON, OLA; LINDEN, TORBJORN; WIESLANDER, ANDERS
To: GAMBRO LUNDIA AB
Reel/Frame 017179/0504 →
Priority Claims (1)
SE 0203671 · Dec 10, 2002 · national
Continuity (2)
Provisional Application 6043258000 · Dec 10, 2002
Related Publication 20060045794A1 · Mar 2, 2006